{
    "nctId": "NCT00674557",
    "briefTitle": "Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer",
    "officialTitle": "A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 111,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Recurrent disease after 2-3 years of adjuvant treatment with an anti-estrogen (documented by imaging techniques)\n  * Advanced disease that has recurred during or after anti-estrogen therapy\n* Measurable or evaluable disease by conventional techniques, with \u2265 1 lesion that can be followed for response\n\n  * Bone metastases only are eligible provided they have \u2265 1 lytic lesion (not previously irradiated or planned for irradiation) that can be followed by X-ray or CT scanning\n  * Cutaneous skin metastases only are eligible provided the skin lesions are \\> 10 mm and can be followed by good quality photography with a ruler included in the photograph\n* No clinically apparent brain metastases\n* Hormone receptor status must meet 1 of the following criteria:\n\n  * Estrogen receptor-positivity\n\n    * Score \u2265 3 on a scale (range of 0 to 8), or equivalent score from other grading methods, representing the intensity and percentage of positive-staining tumor cells by immunohistochemistry\n    * Greater than or equal to 5 fmol/mg protein by ligand binding assay or ELISA\n  * Progesterone receptor-positivity\n\n    * Score \u2265 3 on a scale (range of 0 to 8) or equivalent score from other grading methods, representing the intensity and percentage of positive-staining tumor cells by immunohistochemistry\n* No HER-2 overexpression, defined as gene amplification by fluorescence in situ hybridization \\[FISH\\] OR 3+ overexpression by IHC)\n\nPATIENT CHARACTERISTICS:\n\n* Postmenopausal as defined by any of the following:\n\n  * Surgical or radiation-induced\n  * No menstrual periods for 12 consecutive months with no other biological or physiological cause in women with an intact uterus\n  * Age \u2265 55 years\n* WHO performance status 0-2\n* Life expectancy \u2265 6 months\n* Hemoglobin \u2265 9.0 g/dL\n* ANC \u2265 1.5 x 10\\^9/L\n* Platelet count \u2265100 x 10\\^9/L\n* Serum bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* ALT and/or AST \u2264 2.5 times ULN (5 times ULN if due to tumor)\n* Creatinine clearance \u2265 50 mL/min\n* No history of malabsorption syndromes or other gastrointestinal disorders that may affect SOD1 inhibitor ATN-224 absorption, including any of the following:\n\n  * Bowel obstruction\n  * Celiac disease\n  * Sprue\n  * Cystic fibrosis\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to SOD1 inhibitor ATN-224, omeprazole (or other proton pump inhibitor), or exemestane\n* No non-malignant systemic disease including active uncontrolled infection\n* No serologic positivity for hepatitis B, hepatitis C, or HIV\n* No concurrent congestive heart failure\n* No history of NYHA class III-IV cardiac disease\n* No other concurrent malignancy, except adequately treated cone-biopsied carcinoma in situ of the uterine cervix, basal cell or squamous cell carcinoma of the skin\n\n  * Cancer survivors who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years, and are deemed at low risk for recurrence are eligible\n* No other condition which, in the investigator's opinion, would not make the patient a good candidate for this study\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from all prior therapy (alopecia allowed)\n* At least 1 year since prior bilateral oophorectomy\n* Prior adjuvant or neoadjuvant treatment with tamoxifen allowed\n* Prior adjuvant therapy with a non-steroidal aromatase inhibitor allowed\n* More than 4 weeks since prior immunotherapy or chemotherapy (6 weeks for nitrosoureas and mitomycin-C)\n* More than 4 weeks since prior major thoracic and/or abdominal surgery\n* More than 3 weeks since prior endocrine therapy\n* More than 4 weeks since prior and no concurrent radiotherapy (except to control pain or prevent fracture)\n* No prior exemestane\n* Concurrent iron-containing vitamins or supplements are allowed\n* No concurrent luteinizing hormone-releasing hormone analog\n* No concurrent oral bisphosphonates (IV bisphosphonates allowed)\n* No concurrent chronic steroid therapy for concurrent illness or cancer (short-term steroid use for concurrent illness allowed \\[e.g., for acute asthma\\])\n* No concurrent copper- or zinc-containing vitamins or supplements\n* No concurrent participation in another interventional clinical study (participation in an observational study allowed)\n* No other concurrent copper-binding drug (e.g., penicillamine or trientine)\n* No other concurrent anticancer therapy or investigational agent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}